Olin Corporation shares may be undervalued by 16.3% according to a widely followed valuation narrative, which sets a fair value of $26.29 against a recent close of $22.01. The narrative hinges on structural cost reduction initiatives, including the Beyond250 program and Epoxy cost optimization, expected to deliver $70–90 million in annual run-rate savings by the end of 2025, with additional reductions from the Stade, Germany facility in 2026. These measures are projected to improve net margins and earnings quality, supporting a future earnings multiple below many large chemicals peers. However, the thesis could be challenged if prolonged global overcapacity pressures chlor alkali pricing or if Winchester margins remain constrained by weak demand and higher input costs.
Olin CorporationArticle states Olin is 16.3% undervalued based on cost-cutting narrative and improved margins.